Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 2
2011 1
2013 4
2014 8
2015 6
2016 14
2017 13
2018 12
2019 21
2020 19
2021 38
2022 38
2023 26
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

191 results

Results by year

Filters applied: . Clear all
Page 1
Eculizumab versus rituximab in generalised myasthenia gravis.
Nelke C, Schroeter CB, Stascheit F, Pawlitzki M, Regner-Nelke L, Huntemann N, Arat E, Öztürk M, Melzer N, Mergenthaler P, Gassa A, Stetefeld H, Schroeter M, Berger B, Totzeck A, Hagenacker T, Schreiber S, Vielhaber S, Hartung HP, Meisel A, Wiendl H, Meuth SG, Ruck T. Nelke C, et al. Among authors: ruck t. J Neurol Neurosurg Psychiatry. 2022 May;93(5):548-554. doi: 10.1136/jnnp-2021-328665. Epub 2022 Mar 4. J Neurol Neurosurg Psychiatry. 2022. PMID: 35246490 Free PMC article.
Primary Angiitis of the CNS: A Systematic Review and Meta-analysis.
Beuker C, Strunk D, Rawal R, Schmidt-Pogoda A, Werring N, Milles L, Ruck T, Wiendl H, Meuth S, Minnerup H, Minnerup J. Beuker C, et al. Among authors: ruck t. Neurol Neuroimmunol Neuroinflamm. 2021 Oct 18;8(6):e1093. doi: 10.1212/NXI.0000000000001093. Print 2021 Nov. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34663675 Free PMC article.
Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial.
Schoser B, Roberts M, Byrne BJ, Sitaraman S, Jiang H, Laforêt P, Toscano A, Castelli J, Díaz-Manera J, Goldman M, van der Ploeg AT, Bratkovic D, Kuchipudi S, Mozaffar T, Kishnani PS; PROPEL Study Group. Schoser B, et al. Lancet Neurol. 2021 Dec;20(12):1027-1037. doi: 10.1016/S1474-4422(21)00331-8. Lancet Neurol. 2021. PMID: 34800400 Clinical Trial.
Current Biomarker Strategies in Autoimmune Neuromuscular Diseases.
Oeztuerk M, Henes A, Schroeter CB, Nelke C, Quint P, Theissen L, Meuth SG, Ruck T. Oeztuerk M, et al. Among authors: ruck t. Cells. 2023 Oct 15;12(20):2456. doi: 10.3390/cells12202456. Cells. 2023. PMID: 37887300 Free PMC article. Review.
Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients.
Nelke C, Stascheit F, Eckert C, Pawlitzki M, Schroeter CB, Huntemann N, Mergenthaler P, Arat E, Öztürk M, Foell D, Schreiber S, Vielhaber S, Gassa A, Stetefeld H, Schroeter M, Berger B, Totzeck A, Hagenacker T, Meuth SG, Meisel A, Wiendl H, Ruck T. Nelke C, et al. Among authors: ruck t. J Neuroinflammation. 2022 Apr 12;19(1):89. doi: 10.1186/s12974-022-02448-4. J Neuroinflammation. 2022. PMID: 35413850 Free PMC article.
191 results